Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Ongoing MDS clinical trials to look out for

Daniel Pollyea • 10 Dec 2021
ASH 2021
Myelodysplastic Syndromes Magrolimab Pevonedistat Sabatolimab Venetoclax

Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, comments on novel treatments targeting myelodysplastic syndromes (MDS) under development including pevonedistat, a NEDD8-activating enzyme (NAE) inhibitor, and sabatolimab, an anti-TIM-3 antibody. Dr Pollyea additionally highlights venetoclax and magrolimab, anti-CD47 monoclonal antibody, which are both undergoing clinical trials. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Daniel Pollyea

1:08
The importance of predicting venetoclax response in patients with AML
Daniel Pollyea • 7 Sep 2023
1:11
Varied outcomes in patients with AML harboring poor-risk cytogenetics with or without TP53 mutation
Daniel Pollyea • 7 Sep 2023
1:00
The potential use of multi-gene molecular MRD testing in AML
Daniel Pollyea • 7 Sep 2023
1:13
Addressing whether AML with monocytic features should be considered a distinct clinical entity
Daniel Pollyea • 7 Sep 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals